|
π
|
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
22 auth.
D. Provan,
D. Arnold,
J. Bussel,
B. Chong,
N. Cooper,
T. Gernsheimer,
W. Ghanima,
B. Godeau,
T. GonzΓ‘lezβLΓ³pez,
J. Grainger,
...
M. Hou,
C. Kruse,
V. Mcdonald,
M. Michel,
A. Newland,
S. Pavord,
F. Rodeghiero,
M. Scully,
Y. Tomiyama,
R. Wong,
F. Zaja,
D. Kuter
|
9 |
2019 |
9
π
|
|
π
|
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.
7 auth.
M. Scully,
V. Mcdonald,
J. Cavenagh,
B. Hunt,
I. Longair,
H. Cohen,
...
S. Machin
|
8 |
2011 |
8
π
|
|
π
|
Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.
19 auth.
M. Scully,
M. Thomas,
M. Underwood,
H. Watson,
K. Langley,
R. Camilleri,
A. Clark,
D. Creagh,
R. Rayment,
V. Mcdonald,
...
A. Roy,
G. Evans,
Siobhan McGuckin,
F. N. NΓ Γinle,
R. Maclean,
W. Lester,
M. Nash,
R. Scott,
P. Oβ Brien
|
7 |
2014 |
7
π
|
|
π¬
|
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
J. Westwood,
H. Webster,
Siobhan McGuckin,
V. Mcdonald,
S. Machin,
M. Scully
|
7 |
2013 |
7
π¬
|
|
π
|
Evaluation of laboratory assays for antiβplatelet factor 4 antibodies after ChAdOx1 nCOVβ19 vaccination
8 auth.
S. Platton,
Andrew Bartlett,
P. Maccallum,
M. Makris,
V. Mcdonald,
Deepak Singh,
...
M. Scully,
S. Pavord
|
6 |
2021 |
6
π
|
|
π¦
|
Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura
V. Mcdonald,
K. Manns,
I. Mackie,
S. Machin,
M. Scully
|
6 |
2010 |
6
π¦
|
|
π¬
|
Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link
M. Scully,
J. Brown,
R. Patel,
V. Mcdonald,
C. Brown,
S. Machin
|
6 |
2010 |
6
π¬
|
|
π
|
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
26 auth.
F. Alwan,
C. Vendramin,
K. Vanhoorelbeke,
K. Langley,
V. Mcdonald,
S. Austin,
A. Clark,
W. Lester,
R. Gooding,
T. Biss,
T. Dutt,
N. Cooper,
O. Chapman,
T. Cranfield,
K. Douglas,
...
H. Watson,
J. V. van Veen,
Keith R Sibson,
W. Thomas,
L. Manson,
Q. Hill,
S. Benjamin,
D. Ellis,
J. Westwood,
M. Thomas,
M. Scully
|
6 |
2017 |
6
π
|
|
π
|
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.
10 auth.
J. Westwood,
M. Thomas,
F. Alwan,
V. Mcdonald,
S. Benjamin,
W. Lester,
...
G. Lowe,
T. Dutt,
Q. Hill,
M. Scully
|
6 |
2017 |
6
π
|
|
π
|
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
29 auth.
D. Kuter,
M. Efraim,
J. Mayer,
M. TrnΔnΓ½,
V. Mcdonald,
R. Bird,
Thomas Regenbogen,
M. Garg,
Z. Kaplan,
N. Tzvetkov,
P. Choi,
A. G. Jansen,
M. Kostal,
R. Baker,
J. Gumulec,
...
Eun-Ju Lee,
I. Cunningham,
Isaac Goncalves,
M. Warner,
R. Boccia,
T. Gernsheimer,
W. Ghanima,
O. Bandman,
R. Burns,
A. Neale,
Dolca Thomas,
P. Arora,
Beiyao Zheng,
N. Cooper
|
6 |
2022 |
6
π
|
|
π¬
|
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
A. Newland,
Eun-Ju Lee,
V. Mcdonald,
J. Bussel
|
5 |
2018 |
5
π¬
|
